Kevin M. Lalande is Director at LUMOS PHARMA, INC. (LUMO). They have made 12 open-market trades across 3 companies since 2015, most recently 2024-12-12.
CIK 0001587800
8 open-market purchases totalling $4.0M since 2021, against 4 sales. Across 8 scored buys the stock is down 18.9% at ninety days, and 22.5 points behind the S&P over the same stretch.
8 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 63% | 50% | 25% |
| Avg Move | +6.0% | +1.9% | -18.9% |
| Alpha | +6.0% | +2.6% | -22.5% |
| Scored | 8 | 8 | 8 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MTEM | BUY | 2022-06-13 | 2022-06-21 | $0.89 | $198K | -2.4% | +8.1% | -16.8% |
| LUMO | BUY | 2021-09-08 | 2021-09-10 | $11.21 | $224K | +1.3% | -7.1% | -29.5% |
| LUMO | BUY | 2021-09-02 | 2021-09-07 | $11.22 | $274K | -11.1% | -18.4% | -39.3% |
| LUMO | BUY | 2021-08-30 | 2021-09-01 | $10.67 | $269K | -11.6% | -15.2% | -31.3% |
| LUMO | BUY | 2021-08-25 | 2021-08-27 | $10.11 | $314K | +4.0% | -6.8% | -29.4% |
| LUMO | BUY | 2021-08-20 | 2021-08-24 | $9.09 | $1.2M | +14.6% | +8.1% | -18.6% |
| LUMO | BUY | 2021-08-17 | 2021-08-19 | $8.63 | $809K | +30.4% | +20.0% | +2.0% |
| LUMO | BUY | 2021-08-12 | 2021-08-16 | $7.79 | $724K | +22.6% | +26.6% | +11.7% |
| MTEM | SELL | 2020-09-16 | 2020-09-18 | $13.05 | $6.5M | -9.2% | -7.9% | -20.7% |
| MTEM | SELL | 2020-05-20 | 2020-05-22 | $16.51 | $9.9M | -9.3% | -9.8% | -27.3% |
| LDRH | SELL | 2015-06-10 | 2015-06-12 | $44.77 | $37K | -19.2% | -0.2% | -0.2% |
| LDRH | SELL | 2015-03-02 | 2015-03-04 | $38.50 | $235K | -19.2% | -0.2% | -0.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.